Role of OPG/RANKL/RANK axis on the vasculature

Histology and Histopathology

Volumn 23, Issue 4, 2008, Pages 497-506

  Papadopouli, Aikaterini E ^a   Klonaris, Christos N ^a   Theocharis, Stamatios E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

OPG; RANK; RANKL; Vascular calcification

Indexed keywords

MUS;

EID: 84863981783     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Anand D., Lahiri A., Lim E., Hopkins D. and Corder R. (2006). The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J. Am. Coll Cardiol. 47, 1850-1875.
2. Anderson C.E. and Parker J. (1966). Invasion and resorption in endochondrial ossification. An electron microscopic study. J. Bone Joint Surg. 48, 899-914.
3. Avignon A., Sultan A., Piot C., Elaerts S., Cristol J. and Dupuy A. (2005). Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28, 2176-2180.
4. Baker S.J. and Reddy E.P. (1998). Modulation of life and death by the TNF receptor superfamily. Oncogene 17, 3261-3270.
5. Bostrom K., Watson K.E., Horn S., Wortham C., Herman I.M. and Demer L.L. (1993). Bone morphogenetic protein expression in human atherosclerotic lesions. J. Clin. Invest. 91, 1800-1809.
6. Brandstrom H., Bjorkmann T. and Ljunggren O. (2001). Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem. Biophys. Res. Commun. 280, 831-835.
7. Browner W., Lui L. and Cumming S. (2001). Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J. Clin. Endocrinol. Metab. 86, 631-637.
8. Bucay N., Sarosi I., Dunstan C., Morony S., Tarpley J., Capparelli C., Scully S., Tan H., Xu W., Lacey D., Boyle W. and Simonet W. (1998). Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268
9. Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., Kelley M., Hsu H., Boyle W., Dunstan C., Hu S. and Lacey D. (1999). The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538.
10. Chinnaiyan A.M., O'Rourke K., Yu G.L., Lyons R.H., Garg M., Duan D.L., Xing L., Gentz R., Ni J. and Dixit V.M. (1996). Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 990-992.
11. Clinton S.K., Underwood R., Hayes L., Sherman M.L., Kufe D.W. and Libby P. (1992). Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am. J. Pathol. 140, 301-316.
12. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W. and Osdoby P. (2001). Receptor activator of NF-OB and osteoprotegerin expression by human microvascular cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276, 20659-20672.
13. Demer L.L., Watson K.E. and Bostrom K. (1994). Mechanism of calcification in atherosclerosis. Trends Cardiovasc. Med. 4, 45-49.
14. Dhore C.R., Cleutjens J.P., Lutgens E., Cleutjens K.B., Geusens P.P., Kitslaar P.J., Tordoir J.H., Spronk H.M., Vermeer C. and Daemen M.J. (2001). Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 21, 1998-2003.
15. Dougall W., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M., Maliszewski C., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P., Peschon J. and Schuh J. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2414-2424.
16. Eriksson A.E., Cousens L.S., Weaver L.H. and Matthews B.W. (1991). Three dimensional structure of human basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 88, 3441-3445.
17. Feldman T., Glagov S. and Carroll J.D. (1993). Restenosis following successful balloon valvuloplasty: bone formation in aortic valve leaflets. Cathet. Cardiovasc. Diagn. 29, 1-7.
18. Fiore S. and Serhan C.N. (1990). Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J. Exp. Med. 172, 1451-1457
19. Gerber H.P. and Ferrara N. (2000). Angiogenesis and bone growth. Trends Cardiovasc. Med. 10, 223-228.
20. Gerrity R.G. and Naito H.K. (1980). Ultrastructural identification of monocytederived foam cells in fatty streak lesions. Artery 8, 208-214.
21. Giachelli C., Bae N., Lombardi D., Majesky M. and Schwartz S. (1991). Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem. Biophys. Res. Commun. 177, 867-873.
22. Giachelli C. M, Bae N., Almeida M., Denhardt D.T., Alpers C.E. and Schwart S.M. (1993). Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92, 1686-1696.
23. Glass C. and Witztum J. (2001). Atherosclerosis: The road ahead. Cell 104, 503-516.
24. Golledge J., McCann M., Mangan S., Lam A. and Karan M. (2004). Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35, 1636-1641.
25. Hak A., Pols H., van Hemert A., Hofman A. and Witteman J. (2000). Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler. Thromb. Vasc. Biol. 20, 1926-1931.
26. Hilton M.J., Gutierrez L., Zhang L., Moreno P.A., Reddy M., Brown N., Tan Y., Hill A. and Wells D.E. (2001). An integrated physical map of 8q22-q24: use in positional cloning and deletion analysis of Langer-Giedion syndrome. Genomics 71, 192-199.
27. Hirota S., Imakita M., Kohri K., Ito A., Morii E., Adachi S., Kim H.M., Kitamura Y., Yutani C. and Nomura S. (1993). Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am. J. Pathol. 143, 1003-1008.
28. Hofbauer L. and Heufelder A. (2001). Role of receptor activator of nuclear factor-nB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79, 243-253.
29. Hofbauer L. and Schoppet M. (2001). Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 358, 257-259.
30. Hofbauer L. and Schoppet M. (2004). Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular disease. JAMA 292, 490-495
31. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C. and Riggs B.L. (1999). Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140, 4367-4370.
32. Hofbauer L.C., Shui C., Riggs B.L., Dunstan C.R., Spelsberg T.C., O'Brien T. and Khosla S. (2001). Effects of immunosuppressants on receptor activator of NF-rB ligand and osteoprotegerin production by human osteoblastic and coronary smooth muscle cells. Biochem. Biophys. Res. Commun. 280, 334-339. Hunt J.L., Fairman R., Mitchell M.E., Carpenter J.P., Golden M., Khalapyan T., Wolfe M., Neschis D., Milner R., Scoll B,. Cusack A.
33. Hunt J.L. *Fairman R.*Mitchell M.E.*Carpenter J.P.*Golden M.*Khalapyan T.*Wolfe M.*Neschis D.*Milner R.*Scoll B.*Cusack A.*Mohler III E.R.(2002). Bone formation in carotid plaques: a clinicopathological study. Stroke 33, 1214-1219.
34. Ikeda T., Shirasawa T., Esaki Y., Yoshiki S. and Hirokawa K. (1993). Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J. Clin. Invest. 92, 2814-2820.
35. Itoh N. and Nagata S. (1993). A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J. Biol. Chem. 268, 10932-10937.
36. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K. and Nishizawa Y. (2002). Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106, 1192-1194.
37. Kaden J., Bickelhaupt S., Grobholz R., Haase K., Sarikoc A., Kilie R., Brueckmann M., Lang S., Zahn I., Vahl C., Hagl S., Dempfle C. and Borggrefe M. (2004). Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J. Mol. Cell Cardiol. 36, 57-66.
38. Kiel D., Kauppila L., Cupples L., Hannan M., O'Donnell C. and Wilson P. (2001). Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif. Tissue Int. 68, 271-276.
39. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W. and Willeit J. (2004). Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109, 2175-2180.
40. Knudsen S., Foss C., Poulsen P., Andersen N., Mogensen C. and Rasmussen L. (2003). Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur. J. Endocrinol. 149, 39-42.
41. Kong Y., Yoshida H., Sarosi I., Tan H., Timms E., Capparelli C., Morony S., Oliveira-dos Santos A., Van G., Itie A., Khoo W., Wakeham A., Dunstan C., Lacey D., Mak T., Boyle W. and Penninger J. (1999). OPG is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397, 315-323
42. Kong Y.Y., Boyle W.J. and Penninger J.M. (2000). Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol. Today 21, 495-502.
43. Kwon B.S., Wang S., Udagawa N., Haridas V., Lee Z.H., Kim K.K., Oh K.O., Greene J., Li Y., Su J., Gentz R., Aggarwal B.B. and Ni J. (1998). TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 12, 845-854.
44. Lacey D., Timms E., Tan H., Kelley M., Dunstan C., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J. and Boyle W. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
45. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G. and Qiu W. et al. (2000). Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157, 435-448.
46. Lee S.Y., Kaufmann D.R., Mora A.L., Santana A., Boothby M. and Choi Y. (1998). Stimulus-dependent synergism of the antiapoptotic tumor necrosis factor receptor-associated factor 2 (TRAF2) and nuclear factor-kB pathways. J. Exp. Med. 188, 1381-1384.
47. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V. and Ferrara N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
48. Makiishi-Shimobayashi C., Tsujimura T., Iwasaki T., Yamada N., Sugihar A., Okamura H., Hayashi S. and Terada N. (2001). Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem. Biophys. Res. Commun. 281, 361-366.
49. Matsuzaki K., Udagawa N., Takahashi N., Yamaguchi K., Yasuda H., Shima N., Morinaga T., Toyama Y., Yabe Y., Higashio K. and Suda T. (1998). Osteoclast differentiation factor (ODF) induces osteoclastlike cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246, 199-204.
50. Merkel K.D., Erdmann J.M., McHugh K.P., Abu-Amer Y., Ross F.P. and Teitelbaum S.L. (1999). Tumor necrosis factor-a mediates orthopedic implant osteolysis. Am. J. Pathol. 154, 203-210.
51. Min H., Morony S., Sarosi I., Dunstan C., Capparelli C., Scully S., Van G., Kaufman S., Kostenuik P., Lacey D., Boyle W. and Simonet W. (2000). Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembing osteoclastogenesis. J. Exp. Med. 192, 463-474.
52. Mizuno A., Murakami A., Nakagawa N., Yasuda H., Tsuda E., Morinaga T. and Higashio K. (1998). Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. Gene 215, 339-343.
53. Moran C., McCann M., Karan M. and Norman P. (2005). Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 111, 3119-3125
54. Nakagawa N., Yasuda H., Yano K., Mochizuki S., Kobayashi N., Fujimoto H., Shima N., Morinaga T., Chikazu D., Kawaguchi H. and Higashio K. (1999). Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem. Biophys. Res. Commun. 265, 158-163.
55. Onyia J.E., Miles R.R., Yang X., Halladay D.L., Hale J., Glasebrook A., McClure D., Seno G., Churgay L., Chandrasekhar S. and Martin T.J. (2000). In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J. Bone Miner. Res. 15, 863-871.
56. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M. and O'Brien K.D. (1994). Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90, 844-853.
57. Parhami F., Morrow A., Balucan J., Leitinger N., Watson A., Tintut Y., Berliner J. and Demer L. (1997). Lipid oxidation products have opposite effects on calcifying vascular cells and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17, 680-687.
58. Price P., Faus S. and Williamson M. (2000). Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler. Thromb. Vasc. Biol. 20, 317-327
59. Price P., June H., Buckley J. and Williamson M. (2001). Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 21, 1610-1616.
60. Romanov Y.A., Svintsitskaya V.A. and Smirnov V.N. (2003). Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 21, 105-110.
61. Rosenfeld M.E., Yla-Herttuala S., Lipton B.A., Ord V.A., Witztum J.L. and Steinberg D. (1992). Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am. J. Pathol. 140, 291-300.
62. Rutsch F. and Terkeltaub R. (2003). Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. Curr. Opin. Rheumatol. 15, 302-310.
63. Saika M., Inoue D., Kido S. and Matsumoto T. (2001). 17ß-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-l. Endocrinology 142, 2205-2212.
64. Saito Y., Yamagishi T., Nakamura T., Ohyama Y., Aizawa H., Suga T., Matsumura Y., Masuda H., Kurabayashi M., Kuro-o M., Nabashima Y. and Nagai R. (1998). Klotho protein protects against endothelial dysfunction. Biochem. Biophys. Res. Commun. 248, 324-329.
65. Sattler A., Schoppet M., Schaefer J. and Hofbauer L (2004). Novel aspects on RANKL ligand and osteoprotegerin in osteoporosis and vascular disease. Cacif. Tissue Int. 74, 103-106.
66. Schoppet M., Preissner K. and Hofbauer L. (2002). RANKL ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol. 22, 549-553
67. Schoppet M., Sattler A., Schaefer J., Herzum M., Maisch B. and Hofbauer L. (2003). Increased osteoprotegerin serum leveles in men with coronary artery disease. J. Clin. Endocrinol. Metab. 88, 1024-1028.
68. Schoppet M., Al-Fakhri N., Franke F., Katz N., Barth P., Maisch B., Preissner K. and Hofbauer L. (2004). Localization of osteoprotegerin, tumor necrosis factor related apoptosis-inducing ligand, and receptor activator of nuclear factor-lB in Monckeberg's sclerosis and atherosclerosis. J. Clin. Endocrinol. Metab. 89, 4104-4112.
69. Shanahan C.M., Cary N.R., Metcalfe J.C. and Weissberg P.L. (1994). High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J. Clin. Invest. 93, 2393-2402.
70. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M-S., Lüthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Eliott R., Colombero A., Tan H-L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Amgen E.S.T. Program and Boyle W.J. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89,159-161.
71. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T. and Martin T.J. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357.
72. Takai H., Kanematsu M., Yano K., Tsuda E., Higashio K., Ikeda K., Watanabe K. and Yamada Y. (1998). Transforming growth factor-ß stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem. 273, 27091-27096.
73. Tan K.B., Harrop J., Reddy M., Young P., Terrett J., Emery J., Moore G. and Truneh A. (1997). Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoieticcells. Gene 204, 35-46.
74. Tanimura A., McGregor D.H. and Anderson H.C. (1983). Matrix vesicles in atherosclerotic calcification. Proc. Soc. Exp. Biol. Med. 172, 173-177.
75. Tintut Y., Patel J., Parhami F. and Demer L.L. (2000). Tumor necrosis factor-ffpromotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102, 2636-2642
76. Tintut Y., Alfonso Z., Saini T., Radcliff K., Watson K., Bostrom K. and Demer L.L. (2003). Multilineage potential of cells from the artery wall. Circulation 108, 2505-2510.
77. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., Squire I., Gullestad L., Bollerslev J., Dickstein K. and Aukrust P. (2004). Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. JACC 44, 1970-1976.
78. Vidal O.N., Sjogren K., Eriksson B.I., Ljunggren O. and Ohlsson C. (1998). Osteoprotegerin mRNA is increased by interleukin-1(in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 248, 696-700.
79. Vik A., Mathiesen E., Noto A., Sveinbjornsson B., Brox J. and Hansen J. (2007). Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 191, 128-134.
80. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., Timour M.S., Gerhart M.J., Schooley K.A., Smith C.A., Goodwin R.G. and Rauch C.T. (1997). TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16, 5386-5397.
81. Wallin R., Cain D., Hutson S., Sane D. and Loeser R. (2000). Modulation of the binding of matrix Gla protein (MGP) to bone morphogenic protein-2 (BMP-2). Thromb. Haemost. 84, 1039-1044.
82. Walsh M. and Choi Y. (2003). Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14, 251-263.
83. Wan M., Shi X., Feng X. and Cao X. (2001). Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegerin gene expression. J. Biol. Chem. 276, 10119-10125.
84. Wong B.R., Rho J., Arron J., Robbinson E., Orlinik J., Chao M., Kalachikov S., Cayani E., Bartlett F. III, Frankel W., Lee S. and Choi Y. (1997). TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194.
85. Yamaguchi K., Kinosaki M., Goto M., Kobayashi F., Tsuda E., Morinaga T. and Higashio K. (1998). Characterization of structural domains of human Osteoclastogenesis inhibitory factor. J. Biol. Chem. 273, 5117-5123.
86. Yamashita T., Okada S., Higashio K., Nabeshima Y. and Noda M. (2002). Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. Endocrinology 143, 4711-4717.
87. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T. and Higashio K. (1998a). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337.
88. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomayasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N. and Suda T. (1998b). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci USA 95, 3597-3602.
89. Yun T.J., Chaudhary P.M., Shu G.L., Frazer J.K., Ewings M.K., Schwartz S.M., Pascual V., Hood L.E. and Clark E.A. (1998). OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161, 6113-6121.
90. Yun T., Tallquist M., Aicher A., Rafferty K., Marshall A., Moon J., Ewings M., Mohaupt M., Herring S. and Clark E. (2001). Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166, 1482-1491.
91. Zhang J.D., Cousens L.S., Barr P.J. and Sprang S.R. (1991). Threedimensional structure ofhuman basic fibroblast growth factor, a structural homolog of interleukin-1. Proc. Natl. Acad. Sci. USA 88, 3446-3450.
92. Ziegler S., Kudlacek S., Luger A. and Minar E. (2005). Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182, 175-180.